HCPCS Code J2941: Injection, somatropin, 1 mg billing guide

Key takeaways

HCPCS Code J2941 describes injection, somatropin, 1 mg, so one billed unit equals 1 mg administered by a provider

Medicare Part B pays for J2941 only when your staff gives the injection in an office or outpatient setting

Somatropin sits on the self-administered drug exclusion list, so a patient injecting at home falls to the Part D benefit

SEROSTIM, Genotropin, Norditropin, Omnitrope, and Humatrope all crosswalk to J2941, so the NDC identifies the exact product billed

Practice management software like Pabau tracks units, attaches the NDC, and keeps J2941 claims clean before they leave the practice

HCPCS Code J2941 is the HCPCS Level II J-code for injection, somatropin, 1 mg. One billed unit equals 1 mg of somatropin administered by a provider, so unit math is the first thing to get right.

Coverage is where J2941 gets awkward. Somatropin sits on the Medicare self-administered drug exclusion list, so Part B pays only when your staff gives the injection.

This reference covers unit calculation, the NDC crosswalk, Part B reimbursement, covered diagnoses, and the denials that follow when a piece is missing.

HCPCS Code J2941: Definition and code details

J2941 is a CMS-maintained HCPCS Level II J-code for physician-administered drug billing. It describes a single injection of somatropin at 1 mg per unit. Billers use it in outpatient and office settings when a provider gives the drug to the patient directly.

Somatropin overview: The drug behind HCPCS Code J2941

Somatropin is a recombinant DNA-derived form of human growth hormone (rhGH). It is structurally identical to the growth hormone the pituitary gland produces. Several branded products crosswalk to J2941, including SEROSTIM, Genotropin, Norditropin, Omnitrope, and Humatrope.

The brands do not share the same label. SEROSTIM, made by EMD Serono, is the product approved for HIV-associated wasting, while the others carry growth-related indications. So the brand on the vial shapes which diagnosis will support the claim.

Practices offering hormone therapies use HRT clinic software to hold that documentation alongside the prescription management record behind every dose.

FDA-approved indications for somatropin products billed under J2941 include:

• Growth hormone deficiency (GHD) in adults and children
• HIV-associated wasting or cachexia (the SEROSTIM indication)
• Turner syndrome
• Short stature associated with Noonan syndrome
• Short bowel syndrome in adults
• Idiopathic short stature in children

Payer coverage may not extend to every FDA-approved use. Check medical necessity criteria against the applicable Local Coverage Determination (LCD) or National Coverage Determination (NCD) before you submit a claim.

J2941 billing guidelines and units

Each billed unit of J2941 equals exactly 1 mg of somatropin. Take the prescribed dose in milligrams and use that figure as the unit count. A 6 mg dose is 6 units.

Round to the nearest whole unit per payer guidance, because fractional units usually trigger an edit. Standardized medical documentation keeps the dose given and the dose billed in step.

J2941 is a buy-and-bill code. The practice purchases somatropin from the manufacturer or a specialty pharmacy, administers it, and then bills the payer for the drug and the administration. Place of service must show an outpatient or office setting.

Bill the administration separately with the right injection code, usually CPT 96372 for a therapeutic subcutaneous injection. The AAPC HCPCS lookup tool confirms current descriptor text while you prepare the claim.

Medicare Part B reimbursement for HCPCS Code J2941

Medicare Part B covers physician-administered somatropin under the buy-and-bill model. Reimbursement follows the CMS Physician Fee Schedule and uses the Average Sales Price (ASP) methodology.

The standard Part B drug rate is ASP+6%, but the quarterly figure moves. A rate from last quarter may not be the current allowable, so check before you quote a number.

Key Medicare billing requirements for J2941 claims:

• The drug must be physician-administered, not self-administered by the patient
• The National Drug Code (NDC) must appear on the claim in the required format
• A covered ICD-10-CM diagnosis code must establish medical necessity
• Prior authorization may apply, depending on the Medicare Advantage or supplemental plan
• Place of service must match an appropriate outpatient or office setting

Self-administered drug exclusion and HCPCS Code J2941

Medicare Part B does not cover drugs that patients usually administer themselves. That exclusion is documented in CMS Article A52571, and somatropin appears on the list because home injection is the norm. This is the most misread coverage rule attached to J2941.

Coverage turns on who gives the injection and where. When a physician or qualified clinical staff member administers it in an office or outpatient facility, Part B can pay J2941. When the patient injects at home, the dose belongs to the Part D benefit instead.

Each Medicare Administrative Contractor publishes its own self-administered drug list, so read the one that applies to your region. Insurance eligibility verification at booking settles the question before the vial is opened.

• Covered: Provider-administered in an office or outpatient setting, documented in the medical record
• Not covered under Part B: Patient injects at home, even when the same physician prescribed the drug
• Documentation needed: A record that staff administered the injection, plus route, site, date, dose, and lot number

Prior authorization and coverage criteria for J2941

Prior authorization requirements for J2941 vary by payer. Traditional Medicare fee-for-service usually does not require authorization for growth hormone administration. Medicare Advantage plans, Medicaid programs, and commercial payers frequently do require it before the first dose. Skipping that step is one of the most common causes of a J2941 denial.

The prior authorization process runs on evidence, so gather it before you request approval. Digital intake forms capture the lab values and clinical notes a reviewer will ask for.

Common documentation requirements for J2941 prior authorization:

• Growth hormone deficiency: IGF-1 levels below normal, stimulation test results, and clinical notes confirming the diagnosis
• HIV-associated wasting: HIV diagnosis confirmation, weight loss percentage, and a physician attestation of medical necessity
• Turner syndrome: karyotype confirmation and documented growth failure
• All indications: the current prescription, dosing plan, prescriber credentials, and intended treatment duration

ICD-10 diagnosis codes used with HCPCS Code J2941

Every J2941 claim needs at least one ICD-10-CM code that establishes medical necessity. The payer matches that code against its own coverage criteria for somatropin.

Practices treating several covered indications at once get the most from longevity clinic software that keeps each patient’s diagnosis, dose, and authorization in one record.

Covered diagnoses vary by payer and by plan year. Check the payer’s current LCD or coverage policy before you submit.

NDC to J2941 crosswalk

Medicare requires the National Drug Code (NDC) on all Part B claims for separately payable drugs. Report it in the 11-digit 5-4-2 format, converted from the 10-digit code printed on the manufacturer label. A missing NDC, or the wrong format, generates an automatic rejection.

Product reformulations can change an NDC, so verify against current labeling before submission. CGS Medicare coding guidance sets out the current NDC reporting requirements for HCPCS drug codes.

Report the NDC with the N4 qualifier, then the 11-digit code, then the unit of measure and the quantity administered. Specialty pharmacy slips usually print the 10-digit format. Convert it by adding a leading zero to the segment the labeling specifies. The FDA NDC Directory lists current codes for every somatropin presentation.

Related HCPCS codes for somatropin and growth hormones

J2941 is not the only J-code in growth hormone billing. Knowing which code fits which product prevents denials from incorrect code assignment. Other injectable J-codes such as J2560 and J2720 define their units differently, so read the descriptor before you convert a dose.

Using J3490 or J3590 when J2941 is correct delays reimbursement, because unclassified codes need manual pricing and review. Confirm the code for each somatropin product against the current CMS HCPCS Level II update before billing.

Common claim denials for J2941 and how to avoid them

J2941 claims fail more often than most drug J-codes because five things have to be right at the same time. Units, NDC format, diagnosis specificity, administration setting, and authorization all sit on the same claim line. Miss one and the line denies.

Denial management gets much easier when those five are captured at the point of care instead of reconstructed weeks later. The denial codes reference explains what the codes on a remittance are telling your biller to fix.

How Pabau keeps J2941 claims clean before they go out

A J2941 claim is usually assembled from three places. The dose sits in the treatment note, the NDC on the vial label or pharmacy slip, and the authorization number in somebody’s inbox. Whatever does not get carried across by hand turns into a denial.

Practice management software like Pabau keeps all three in one record. Whoever gives the injection logs the dose, route, site, and lot number at the point of care. The unit count follows from the milligrams entered, so nobody recalculates it later.

Pabau’s claims management software then carries the NDC and the authorization number onto the claim. It submits electronically through the Claim.MD integration, and the remittance returns to the same record. So your biller sees a complete claim before it leaves the practice, rather than a rejection three weeks later.

Bill high-cost injectables without the rework

Pabau tracks somatropin units, attaches the NDC, and submits J2941 claims electronically. Your team spends less time correcting denials and more time with patients.

Book a demo

Conclusion

J2941 is a short descriptor with a complicated coverage rule behind it. Correct units and a correctly formatted NDC clear two of the five checks on the claim. The administration setting, the diagnosis, and the authorization decide the rest.

So settle the payer and the setting before the vial is drawn up. A denial under the self-administered exclusion is not a resubmission problem. The dose belonged to a different benefit, and no amount of rework changes that.

Building that check into scheduling costs a few minutes and saves weeks of chasing. Book a demo to see how Pabau keeps somatropin units, NDCs, and authorization numbers attached to the claim.

Continue your research

Billing another hormone injection? J0970 covers estradiol valerate, with its own unit definition to check before you convert a dose.

Working across other drug J-codes? J2788 shows how a different unit size changes the math on the same claim form.

Wondering where your claims actually go? Claim.MD clearinghouse walks through how an electronic claim reaches the payer and comes back as remittance.

Frequently asked questions